AB‐MDMSBA—Not a Synthetic Cannabinoid Receptor Agonist

Abstract Synthetic cannabinoids remain one of the most prominent classes of New Psychoactive Substances (NPS). The introduction of “blanket bans” has only invigorated the development and emergence of novel compounds. Recently, a putative synthetic cannabinoid, AB‐MDMSBA, was identified in Australia and New Zealand, with little to no pharmacological data on this compound. This current study, therefore, aimed to determine the potential activity of AB‐MDMSBA at the human cannabinoid CB1 receptor. Results revealed AB‐MDMSBA failed to activate cAMP and β‐arrestin 2